Biomarkers in Tissue Samples From Older Women With Breast Cancer
RATIONALE: DNA analysis of tumor tissue may help doctors predict how well patients will respond to treatment.
PURPOSE: This research study is studying biomarkers in tissue samples from older women with breast cancer.
Genetic: DNA analysis
Genetic: mutation analysis
Genetic: polymerase chain reaction
Other: laboratory biomarker analysis
Other: mass spectrometry
Other: medical chart review
|Official Title:||PIK3CA Mutation Status as a Biomarker in Elderly Women With Breast Cancer|
- Breast cancer-free interval of patients with PIK3CA-mutated tumors as compared to wild-type tumors [ Designated as safety issue: No ]
- Overall survival of patients with PIK3CA-mutated tumors [ Designated as safety issue: No ]
- Breast cancer-specific survival of patients with PIK3CA-mutated tumors [ Designated as safety issue: No ]
|Study Start Date:||April 2011|
|Estimated Primary Completion Date:||May 2011 (Final data collection date for primary outcome measure)|
- To validate PIK3CA mutation status as a biomarker in women 70 years or older diagnosed with breast cancer.
OUTLINE: Genomic DNA extracted from archived tumor tissue samples are analyzed for mutation by Sequenom multiplex massARRAY (multiplex PCR and mass spectroscopy). Results are then analyzed by massARRAY TyperAnalyzer v4.0 software. Patients clinical data are also analyzed, including treatment received.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01346579
|Principal Investigator:||Mary Ellen Moynahan, MD||Memorial Sloan Kettering Cancer Center.|